Franklin Resources Inc. Cuts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Franklin Resources Inc. lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 24.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 184,027 shares of the company's stock after selling 59,733 shares during the quarter. Franklin Resources Inc. owned 0.64% of Krystal Biotech worth $28,830,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in KRYS. Norges Bank acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $34,391,000. State Street Corp lifted its stake in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company's stock worth $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech in the 4th quarter valued at about $15,989,000. TimesSquare Capital Management LLC boosted its stake in shares of Krystal Biotech by 39.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after buying an additional 44,646 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after acquiring an additional 28,707 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Trading Down 5.9 %

Shares of KRYS stock traded down $9.97 during trading on Thursday, hitting $158.19. The company's stock had a trading volume of 60,107 shares, compared to its average volume of 293,240. The business has a fifty day moving average of $173.85 and a 200-day moving average of $172.48. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The company has a market cap of $4.56 billion, a PE ratio of 52.66 and a beta of 0.75.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's revenue was up 116.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.30 earnings per share. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

KRYS has been the topic of several research reports. Jefferies Financial Group started coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Citigroup raised their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech has an average rating of "Buy" and a consensus target price of $220.00.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).